Japanese companies Mitsubishi Tanabe Pharma and Hitachi have partnered to improve the efficiency of clinical trials for the development of new drugs.

Under the partnership, the companies will undertake a range of operations to enhance trials using Hitachi’s Artificial Intelligence (AI), an advanced digital technology, so as to reduce the period for development of new drugs, as well as development cost.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Hitachi’s Research & Development Group has developed the AI technology for medical use.

Drug prices in the country are currently under pressure and cheap generic drugs are capturing an increasing share of the market.

“By using AI technology such as natural language processing and deep learning, the companies have confirmed that the time spent to gather information is reduced by about 70%.”

In order to meet this challenge, the companies are searching for a better way to design the trials, which requires a huge amount of time and the know-how, as well as the experience of skilled experts.

To address them, Mitsubishi Tanabe Pharma and Hitachi jointly started considering automated information search and collection at the beginning of last year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

By using AI technology such as natural language processing and deep learning, the companies have confirmed that the time spent to gather information is reduced by about 70%.

Additionally, the accuracy of the data collected and organised is verified, allowing the companies to obtain a perspective on the feasibility of full-scale use.

Furthermore, the companies plan to expand the scope of their collaborative creation to undertake a range of demonstration experiments in the future.

Initially, Hitachi will launch a solution of automated technology for collection of information from medical literature to the pharmaceutical industry in Japan and overseas starting this year.

The solution is planned to be developed through collaborative creation using Hitachi’s IoT platform, ‘Lumada’.